Robert S. Mills, Bob is a 39-year veteran in the pharmaceutical industry. Bob’s expertise ranges across GMP Operations, Clinical Research, Regulatory Affairs and Commercial Operations as well as R&D, IT, Product Development, Technical Services, Manufacturing, Engineering and Quality Assurance. Bob has a large network of industry relationships, as well as a very strong track record successfully managing businesses, delivering quality products, successfully interacting with the FDA, and generating attractive growth through expanding market share and launching exciting new products. Most recently, he was the President and CEO of Scientific Protein Labs (SPL), the US’s leading manufacturer of heparin and pancreatin. Recently, Bob sold SPL to a Chinese pharmaceutical company for 3 times the original purchase price and with milestone payments over the next several years could be as high as 5 times the original purchase price. Prior to SPL, Bob was President of Qualitest Pharmaceuticals, a leading manufacturer and distributor of generic pharmaceuticals. He joined Qualitest in early 2010 with the specific charge to grow the business at a quicker pace. In less than one year, monthly net sales increased by over 50 percent. In late 2010, Qualitest was acquired by Endo Pharmaceuticals for $1.2 billion or 15 times EBITDA. Prior to Qualitest, Bob was recruited to Columbia Laboratories, Inc. in 2001 to solve a worldwide recall issue for the principal product and re-launched the product to the marketing partner within 4 months. He was also responsible for a product with a completely new delivery system being approved on its PDUFA date and after becoming CEO in 2006 more than doubled sales to $36 million in two years. As Vice President and General Manager of Watson/Schein’s solid dose division, after correcting a number of quality and regulatory issues through a voluntary corrective action plan with FDA, the Company received 5 new product approvals. The launch of these products coupled with operational efficiencies resulted in an improvement of profitability in one year by $60 million which was instrumental in Schein being acquired by Watson. Bob served as Vice President of Operations at Alpharma, Inc. from 1993 to 1996. Prior to Alpharma, Bob held various positions with Sanofi including Director-Plant Operations, Rhone-Poulenc Rorer. His business development experience has led to multiple product acquisitions, joint ventures and product divestitures. He was recognized as a finalist for Entrepreneur of the Year for New Jersey in 2009 by Ernst and Young. Bob holds a B.S. Degree from Grove City College and numerous graduate business credits from Temple University.
Dr. Fletcher founded and serves as CEO of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms and large family offices. Bios Research provides fundamental healthcare industry research focused in the biotech and med-tech sub-sectors and through this research Dr. Fletcher has a strong understanding of commercial viability in the marketplace. Dr. Fletcher holds a PhD in Biochemistry from Colorado State University, and serves as a professor at Dallas Baptist University where he teaches Biochemistry, Bioethics, and Cell Biology. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over ten years.
Dr. Idell is a clinical investigator who has been continually funded over the past 30 years by the National Institutes of Health for his work in the areas of acute lung injury and pleural diseases. He is a board-certified internist and pulmonologist who has also directed the Intensive Care Units at Temple University Hospital in Philadelphia and at The University of Texas Health Science Center at Tyler, Texas. He is now Vice President for Research, a Professor of Medicine and Temple Chair of Pulmonary Fibrosis at UTHSCT and Director of an NIH-sponsored Program Project Grant to study the role of the fibrinolytic system in the pathogenesis of lung and pleural disease. Work from that project led to the development of scuPA as a treatment for pleural loculation and of a peptide-based approach to treat acute lung injury and pulmonary fibrosis.
Dr. Idell also continues to manage patients in the UTHSCT Pulmonary Clinic. He has successfully obtained over $27 million in grant support from agencies including the NIH, The American Heart Association, The American Lung Association and various foundations. He is the Director of the Texas Lung Injury Institute of UTHCT and has raised nearly $1 million of philanthropic support for lung injury research to develop novel experimental therapeutics from the community, grateful patients and various foundations in East Texas and has received commitment from the NIH RAID and SMARTT programs to perform IND-enabling studies with his lead therapeutic, LTI-01. In addition to his role as CSO, Dr. Idell also serves as Chair of the Scientific Advisory Board and a Member of the Board of Directors.
Dr. Windsor has spent the last 18 years in the formation and management of life science-based technology ventures and has led technology development and licensing to major pharmaceutical firms as well as public and private companies. Dr. Windsor brings recent leadership experience in pharmaceutical drug development and most recently served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company developing unique formulations for superior drug performance. While at Enavail, Dr. Windsor oversaw all aspects of pharmaceutical drug development, including drug selection, regulatory strategy, preclinical and clinical strategy, GMP manufacturing, and strategic partnering for pharma products.
Prior to his role with Enavail, Dr. Windsor directed portfolio company management for Emergent Technologies Inc. (ETI), an early stage technology venture creation and management company. During his tenure at ETI, Dr. Windsor has served as Managing Director or President for ten of ETI’s portfolio companies and has been involved in the conception, technology licensing, corporate and technical strategic planning, launch, and business development of all of these ventures. Applications areas of these companies span diverse segments within life and material sciences and include pharmaceutical development and manufacturing, drug delivery, and biotechnology.
Prior to joining ETI, he was Founder and Vice President of R&D for Texagen, Inc., a startup focused on genetic and chemical methods for overcoming mechanisms of drug resistance important to medicine and agriculture. At Texagen he directed outsourced research efforts at university labs and third party contract research companies, and he interfaced with corporate partners interested in feasibility studies and in-licensing discussions.
He holds a PhD in Molecular Biology from The University of Texas at Austin, is an invited speaker for both scientific and technology transfer events, and is an inventor on multiple patents and patent applications.